SAR study on inhibitors of GIIA secreted phospholipase A2 using machine learning methods
暂无分享,去创建一个
Yang Li | Aixia Yan | Shengde Zhang | Guang Chen | Zijian Qin | Guipin Tu | A. Yan | Z. Qin | Yang Li | Guang Chen | Guiping Tu | S. Zhang
[1] D. R. Berry,et al. Indole inhibitors of human nonpancreatic secretory phospholipase A2. 3. Indole-3-glyoxamides. , 1996, Journal of medicinal chemistry.
[2] J. Burke,et al. Mechanism of Inhibition of Human Nonpancreatic Secreted Phospholipase A by the Anti-inflammatory Agent BMS-181162 (*) , 1995, The Journal of Biological Chemistry.
[3] G. Lambeau,et al. Inhibition of secreted phospholipase A2. 4-glycerol derivatives of 4,5-dihydro-3-(4-tetradecyloxybenzyl)-1,2,4-4H-oxadiazol-5-one with broad activities. , 2007, Journal of medicinal chemistry.
[4] A. Yan,et al. Computational models for the classification of mPGES-1 inhibitors with fingerprint descriptors , 2017, Molecular Diversity.
[5] M. Büchler,et al. Improved Method for the Determination of Phospholipase A2 Catalytic Activity Concentration in Human Serum and Ascites , 1987, Journal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie.
[6] Chih-Jen Lin,et al. A Practical Guide to Support Vector Classication , 2008 .
[7] K. Tanaka,et al. A novel type of phospholipase A2 inhibitor, thielocin A1 beta, and mechanism of action. , 1992, The Journal of antibiotics.
[8] Nathan Halko,et al. Finding Structure with Randomness: Probabilistic Algorithms for Constructing Approximate Matrix Decompositions , 2009, SIAM Rev..
[9] Isabelle Guyon,et al. Automatic Capacity Tuning of Very Large VC-Dimension Classifiers , 1992, NIPS.
[10] M. Weyant,et al. Knockdown of secretory phospholipase A2 IIa reduces lung cancer growth in vitro and in vivo. , 2012, The Journal of thoracic and cardiovascular surgery.
[11] N. Gensmantel,et al. Discovery of new non-phospholipid inhibitors of the secretory phospholipases A2. , 1994, Journal of medicinal chemistry.
[12] Johann Gasteiger,et al. A new model for calculating atomic charges in molecules , 1978 .
[13] Leo Breiman,et al. Random Forests , 2001, Machine Learning.
[14] Dan Li,et al. ADMET Evaluation in Drug Discovery. 16. Predicting hERG Blockers by Combining Multiple Pharmacophores and Machine Learning Approaches. , 2016, Molecular pharmaceutics.
[15] Y. Miki,et al. A new era of secreted phospholipase A2 , 2015, Journal of Lipid Research.
[16] D. Velmurugan,et al. Celastrol modulates inflammation through inhibition of the catalytic activity of mediators of arachidonic acid pathway: Secretory phospholipase A2 group IIA, 5-lipoxygenase and cyclooxygenase-2. , 2016, Pharmacological research.
[17] W Pruzanski,et al. Cloning and recombinant expression of phospholipase A2 present in rheumatoid arthritic synovial fluid. , 1989, The Journal of biological chemistry.
[18] Tingjun Hou,et al. Constructing and Validating High-Performance MIEC-SVM Models in Virtual Screening for Kinases: A Better Way for Actives Discovery , 2016, Scientific Reports.
[19] Katsutoshi Yamada,et al. Potent inhibitors of secretory phospholipase A2: synthesis and inhibitory activities of indolizine and indene derivatives. , 1996, Journal of medicinal chemistry.
[20] W. Cantor,et al. The sPLA2 Inhibition to Decrease Enzyme Release After Percutaneous Coronary Intervention (SPIDER-PCI) Trial , 2010, Circulation.
[21] David Rogers,et al. Extended-Connectivity Fingerprints , 2010, J. Chem. Inf. Model..
[22] Thomas M. Mavromoustakos,et al. Design of new secreted phospholipase A2 inhibitors based on docking calculations by modifying the pharmacophore segments of the FPL67047XX inhibitor , 2010, J. Comput. Aided Mol. Des..
[23] Tingjun Hou,et al. ADMET evaluation in drug discovery: 15. Accurate prediction of rat oral acute toxicity using relevance vector machine and consensus modeling , 2016, Journal of Cheminformatics.
[24] D. R. Berry,et al. Indole inhibitors of human nonpancreatic secretory phospholipase A2. 2. Indole-3-acetamides with additional functionality. , 1996, Journal of medicinal chemistry.
[25] G. Dive,et al. Design of new potent and selective secretory phospholipase A(2) inhibitors. 6-Synthesis, structure-activity relationships and molecular modelling of 1-substituted-4-[4,5-dihydro-1,2,4-(4H)-oxadiazol-5-one-3-yl(methyl)]-functionalized aryl piperazin/one/dione derivatives. , 2010, Bioorganic & medicinal chemistry.
[26] J. Gasteiger,et al. Autocorrelation of Molecular Surface Properties for Modeling Corticosteroid Binding Globulin and Cytosolic Ah Receptor Activity by Neural Networks , 1995 .
[27] L. Lai,et al. Quinoline-4-methyl esters as human nonpancreatic secretory phospholipase A₂ inhibitors. , 2011, Bioorganic & medicinal chemistry.
[28] Youyong Li,et al. ADMET Evaluation in Drug Discovery. Part 17: Development of Quantitative and Qualitative Prediction Models for Chemical-Induced Respiratory Toxicity. , 2017, Molecular pharmaceutics.
[29] Luhua Lai,et al. Optimization of 5-hydroxytryptamines as dual function inhibitors targeting phospholipase A2 and leukotriene A4 hydrolase. , 2013, European journal of medicinal chemistry.
[30] N. S. Yarla,et al. Synthesis of new secretory phospholipase A2-inhibitory indole containing isoxazole derivatives as anti-inflammatory and anticancer agents. , 2016, European journal of medicinal chemistry.
[31] Youyong Li,et al. ADMET Evaluation in Drug Discovery. 18. Reliable Prediction of Chemical-Induced Urinary Tract Toxicity by Boosting Machine Learning Approaches. , 2017, Molecular pharmaceutics.
[32] K. Tanaka,et al. Cinatrins, a novel family of phospholipase A2 inhibitors. II. Biological activities. , 1992, The Journal of antibiotics.
[33] L. Gomez‐Paloma,et al. Synthesis and pharmacological evaluation of a selected library of new potential anti-inflammatory agents bearing the gamma-hydroxybutenolide scaffold: a new class of inhibitors of prostanoid production through the selective modulation of microsomal prostaglandin E synthase-1 expression. , 2007, Journal of medicinal chemistry.
[34] G. Kokotos,et al. Inhibitors of phospholipase A2 and their therapeutic potential: an update on patents (2012-2016) , 2017, Expert opinion on therapeutic patents.
[35] M. Lehr,et al. Novel 3-dodecanoylindole-2-carboxylic acid inhibitors of cytosolic phospholipase A(2). , 2001, Bioorganic & medicinal chemistry letters.
[36] L. Lai,et al. Discovery of Novel Secretory Phospholipase A2 Inhibitors Using Virtual Screen , 2014, Chemical biology & drug design.
[37] D.M. Mount,et al. An Efficient k-Means Clustering Algorithm: Analysis and Implementation , 2002, IEEE Trans. Pattern Anal. Mach. Intell..
[38] V. Madison,et al. N-(carboxymethyl)-N-[3,5-bis(decyloxy)-phenyl]glycine (Ro 23-9358): a potent inhibitor of secretory phospholipases A2 with antiinflammatory activity. , 1993, Journal of medicinal chemistry.
[39] M. Alcaraz,et al. Synthesis and comparison of the antiinflammatory activity of manoalide and cacospongionolide B analogues. , 1998, Journal of medicinal chemistry.
[40] N. Yoshida,et al. Development of a radioimmunoassay for human group-II phospholipase A2 and demonstration of postoperative elevation. , 1991, Enzyme.
[41] M. Gelb,et al. Development of a potent 2-oxoamide inhibitor of secreted phospholipase A2 guided by molecular docking calculations and molecular dynamics simulations. , 2016, Bioorganic & medicinal chemistry.
[42] J.-P. Wery,et al. Structure-based design of the first potent and selective inhibitor of human non-pancreatic secretory phospholipase A2 , 1995, Nature Structural Biology.
[43] Corinna Cortes,et al. Support-Vector Networks , 1995, Machine Learning.
[44] Gisbert Schneider,et al. Impact of descriptor vector scaling on the classification of drugs and nondrugs with artificial neural networks , 2004, Journal of molecular modeling.
[45] Daisuke Fujioka,et al. A novel anti-inflammatory role for secretory phospholipase A2 in immune complex-mediated arthritis , 2010, EMBO molecular medicine.
[46] Thomas M. Mavromoustakos,et al. Molecular Docking and 3D-QSAR CoMFA Studies on Indole Inhibitors of GIIA Secreted Phospholipase A2 , 2010, J. Chem. Inf. Model..
[47] M. Payá,et al. Synthesis and enzyme inhibitory activities of a series of lipidic diamine and aminoalcohol derivatives on cytosolic and secretory phospholipases A2. , 2000, Bioorganic & medicinal chemistry letters.
[48] Liang Cheng,et al. Expression of group IIA secretory phospholipase A2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma. , 2002, The American journal of pathology.
[49] M. Gelb,et al. Simplified YM-26734 inhibitors of secreted phospholipase A2 group IIA. , 2008, Bioorganic & medicinal chemistry letters.
[50] Johann Gasteiger,et al. Overcoming the Limitations of a Connection Table Description: A Universal Representation of Chemical Species , 1997, J. Chem. Inf. Comput. Sci..
[51] Aixia Guo,et al. Gene Selection for Cancer Classification using Support Vector Machines , 2014 .
[52] N. S. Yarla,et al. Phospholipase A2: A Potential Therapeutic Target in Inflammation and Cancer (In silico, In vitro, In vivo and Clinical Approach) , 2015 .
[53] K. Tanaka,et al. Isolation and biological activity of thielocins: novel phospholipase A2 inhibitors produced by Thielavia terricola RF-143. , 1995, The Journal of antibiotics.
[54] T. Caliński,et al. A dendrite method for cluster analysis , 1974 .
[55] G. Morris,et al. Molecular docking. , 2008, Methods in molecular biology.
[56] M. V. D’Auria,et al. New sesquiterpene derivatives from the sponge Dysidea species with a selective inhibitor profile against human phospholipase A2 and other leukocyte functions. , 2001, Journal of natural products.
[57] R. Reid,et al. Inhibitors of secretory phospholipase A2 group IIA. , 2005, Current medicinal chemistry.
[58] Luhua Lai,et al. Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching. , 2008, Journal of medicinal chemistry.
[59] Marcin Kozak,et al. “A Dendrite Method for Cluster Analysis” by Caliński and Harabasz: A Classical Work that is Far Too Often Incorrectly Cited , 2012 .
[60] Varnavas D. Mouchlis,et al. Inhibition of secreted phospholipases A₂ by 2-oxoamides based on α-amino acids: Synthesis, in vitro evaluation and molecular docking calculations. , 2011, Bioorganic & medicinal chemistry.
[61] Stan Szpakowicz,et al. Machine Learning Applications in Mega-Text Processing , 2010 .
[62] C. Unger,et al. Synthesis and PLA2-inhibitory properties of 2(R)-acetamido-alkylphosphomethanols with a variable aggregate anchor. , 1999, Bioorganic & medicinal chemistry letters.
[63] E. Dennis,et al. Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. , 2011, Chemical reviews.
[64] R. Rosenson,et al. Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease. , 2011, European heart journal.
[65] John M. Knapp,et al. Identification of inhibitors against interaction between pro-inflammatory sPLA2-IIA protein and integrin αvβ3. , 2013, Bioorganic & medicinal chemistry letters.
[66] E. Dennis,et al. Phospholipase A2 Biochemistry , 2009, Cardiovascular Drugs and Therapy.
[67] M. Gelb,et al. The first potent inhibitor of mammalian group X secreted phospholipase A2: elucidation of sites for enhanced binding. , 2006, Journal of medicinal chemistry.
[68] H. Tojo,et al. Increased group II phospholipase A2 in colonic mucosa of patients with Crohn's disease and ulcerative colitis. , 1994, Gut.
[69] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.
[70] J. Bronson,et al. A simple synthesis of biaryl phospholipase A2 inhibitors: Probing hydrophobic effects , 1996 .
[71] Johann Gasteiger,et al. New empirical models of substituent polarisability and their application to stabilisation effects in positively charged species , 1983 .
[72] Luhua Lai,et al. Chemically induced dimerization of human nonpancreatic secretory phospholipase A2 by bis-indole derivatives. , 2008, Journal of medicinal chemistry.
[73] D. R. Berry,et al. Indole inhibitors of human nonpancreatic secretory phospholipase A2. 1. Indole-3-acetamides. , 1996, Journal of medicinal chemistry.
[74] Chang H. Park,et al. Design of new potent and selective secretory phospholipase A2 inhibitors. Part 5: synthesis and biological activity of 1-alkyl-4-[4,5-dihydro-1,2,4-[4H]-oxadiazol-5-one-3-ylmethylbenz-4'-yl(oyl)] piperazines. , 2008, Bioorganic & medicinal chemistry.
[75] L. Lai,et al. Calculating partition coefficient by atom-additive method , 2000 .
[76] M. Ogawa,et al. Overexpression of group II phospholipase A2 in human breast cancer tissues is closely associated with their malignant potency. , 1994, British Journal of Cancer.
[77] S. Wright,et al. Vinylogous hydroxamic acids: 5-lipoxygenase inhibitors , 1992 .
[78] Tingjun Hou,et al. ADME evaluation in drug discovery , 2002, Journal of molecular modeling.
[79] S. Katsumura,et al. Design and synthesis of new secretory phospholipase A2 inhibitor of a phospholipid analog. , 1998, Bioorganic & medicinal chemistry letters.
[80] M. Gelb,et al. Highly specific and broadly potent inhibitors of mammalian secreted phospholipases A2. , 2008, Journal of medicinal chemistry.
[81] M. Alcaraz,et al. A new cacospongionolide inhibitor of human secretory phospholipase A2 from the Tyrrhenian sponge Fasciospongia cavernosa and absolute configuration of cacospongionolides. , 1998, Journal of natural products.
[82] Y. Miki,et al. The Roles of the Secreted Phospholipase A2 Gene Family in Immunology , 2016, Advances in Immunology.
[83] J. Kastelein,et al. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. , 2014, JAMA.